Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients

European Journal of Haematology

Volumn 67, Issue 1, 2001, Pages 30-34

  Taher, Ali ^a,b   Sheikh Taha, Marwan ^c   Koussa, Suzanne ^a   Inati, Adlette ^a   Neeman, Roger ^a,d   Mourad, Fadi ^b  

^a Chronic Care Center Hazmieh   (Lebanon)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^d SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

Deferiprone; Deferoxamine; Iron chelation; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; IRON CHELATING AGENT;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ALLERGY; ARTHRALGIA; ARTHROPATHY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEADACHE; HUMAN; IRON CHELATION; IRON METABOLISM; LEBANON; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; THALASSEMIA; URINARY EXCRETION; ZINC DEFICIENCY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; DEFEROXAMINE; FEMALE; FERRITINS; FOLLOW-UP STUDIES; GROWTH DISORDERS; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; NERVOUS SYSTEM DISEASES; PAIN; PATIENT COMPLIANCE; PYRIDONES; SAFETY; TACHYCARDIA; TREATMENT OUTCOME; ZINC;

EID: 0034883496     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.067001030.x     Document Type: Article

References (29)

1. Iron-chelating therapy and the treatment of thalassemia
2. Pathophysiology of iron overload
3. Iron chelators for thalassemia
4. HBED: A potential alternative to deferoxamine for iron-chelation therapy
5. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
6. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload
7. Iron state and hepatic disease in patients with thalasemia major, treated with long term subcutaneous desferrioxamine
8. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia
9. Iron chelation therapy
10. Design, properties, and effective use of the oral chelator L1 and other α-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia
11. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload
12. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine
13. Oral iron chelation
14. Efficacy and side effects of Deferiprone (L1) in thalassemia patients not compliant with desferrioxamine
15. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload
16. An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major
17. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia
18. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major
19. Results of long term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
20. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major: One year comparison with subcutaneous desferrioxamine
21. Long term assessment of efficacy and safety of L1 an oral iron chelator, in transfusion dependent thalassemia: Indian trial
22. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
23. L1 (1, 2-dimethyl-3hydroxypyrid-4-one) for iron chelation in patients with beta-thalassemia major
24. Long term treatment of transfusion hemosiderosis with the oral iron chelator L1
25. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
26. Combined therapy with deferiprone and desferrioxamine
27. Randomised trial of deferiprone (L1) and deferoxamine (DFO0 in thalassemia major
28. Efficacy of L1 (deferiprone) versus desferrioxamine shown by a randomized multicentric trial